Premium
Improved treatment satisfaction in patients with type 2 diabetes treated with once‐weekly semaglutide in the SUSTAIN trials
Author(s) -
Jendle Johan,
Birkenfeld Andreas L.,
Polonsky William H.,
Silver Robert,
Uusinarkaus Kari,
Hansen Thomas,
HåkanBloch Jonas,
Tadayon Sayeh,
Davies Melanie J.
Publication year - 2019
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.13816
Subject(s) - semaglutide , dulaglutide , placebo , medicine , type 2 diabetes , exenatide , weight loss , patient satisfaction , adverse effect , diabetes mellitus , physical therapy , obesity , surgery , endocrinology , liraglutide , alternative medicine , pathology
Aim To investigate treatment satisfaction with semaglutide, a once‐weekly glucagon‐like peptide‐1 receptor agonist, versus placebo/active comparators in the SUSTAIN clinical trial programme. Methods In SUSTAIN 2–5 and 7, the Diabetes Treatment Satisfaction Questionnaire was used to evaluate patient‐perceived treatment satisfaction, hyperglycaemia and hypoglycaemia. Post hoc subgroup analyses were conducted to explore the effects of gastrointestinal adverse events (GI AEs), weight loss (≥5%) or achieving glycaemic (HbA1c < 7%) targets on treatment satisfaction. Results Overall treatment satisfaction increased from baseline to end of treatment with all treatments across trials. Improvements were significantly greater with semaglutide versus comparators/placebo in SUSTAIN 2–5 (all P < 0.05), and generally greater in patients who achieved versus did not achieve weight loss and glycaemic targets, often with greater improvements with semaglutide 1.0 mg versus comparator/placebo in both weight loss groups. In SUSTAIN 7, improvements in overall treatment satisfaction were generally similar between semaglutide and dulaglutide, irrespective of weight loss or glycaemic control. In SUSTAIN 7, changes in overall treatment satisfaction score were generally lower in patients with versus without GI AEs at week 16 (except dulaglutide 0.75 mg), but similar by week 40. Perceived hyperglycaemia was significantly reduced from baseline to end of treatment with semaglutide versus all comparators/placebo (all P < 0.05). No differences between treatments were observed for perceived hypoglycaemia. Conclusions Semaglutide was associated with significantly greater (SUSTAIN 2–5) or similar (SUSTAIN 7) improvements in overall treatment satisfaction versus comparators/placebo. Improvements in overall treatment satisfaction were generally greater in patients achieving versus not achieving treatment targets. Clinicaltrials.gov : NCT01930188 (SUSTAIN 2), NCT01885208 (SUSTAIN 3), NCT02128932 (SUSTAIN 4), NCT02305381 (SUSTAIN 5) and NCT02648204 (SUSTAIN 7). EudraCT: 2012–004827‐19 (SUSTAIN 2), 2012–004826‐92 (SUSTAIN 3), 2013–004392‐12 (SUSTAIN 4), 2013–004502‐26 (SUSTAIN 5) and 2014–005375‐91 (SUSTAIN 7).